← back to search

Li Liu

Harvard University · US
Area of research
Epidemiology · Oncology
Research interest
Research interests include Liver Disease Diagnosis and Treatment, Cancer Immunotherapy and Biomarkers, Renal cell carcinoma treatment, and Nutritional Studies and Diet.
h-index
59
citations
15,144
works
794
NIH funding
primary concept
Medicine
email

Recent publications

Lactate-Driven IL8+ Tumor-Associated Macrophages Mediate Immunosuppression and Resistance to Immunotherapy in Clear-Cell Renal Cell Carcinoma.
2026cited by 0position: contributordoi
SPP1+ Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8+ T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma
Cancer Immunology Research 2025cited by 13position: middledoi
Comparable survival outcomes in HLA-Matched and haploidentical hematopoietic stem cell transplantation for severe aplastic anemia patients aged 40–50: A CBMTR Registry-based propensity score matching analysis over the last decade
Cancer Letters 2025cited by 11position: middledoi
SPP1+ Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8+ T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma.
2025cited by 8position: contributordoi
Effect of electroacupuncture on vascular remodeling in rats with cerebral ischemia by regulating irisin based on VEGF/Akt/eNOS signaling pathway
Brain Research Bulletin 2025cited by 7position: middledoi
Impact of exercise-based cardiac rehabilitation on cardiopulmonary function and prognosis in ST elevation myocardial infarction after PCI patients in extremely cold regions
BMC Cardiovascular Disorders 2025cited by 3position: middledoi
Puerarin combined with <i>Hericium erinaceus</i> insoluble dietary fiber alleviates obesity induced by high-fat diet through regulating the glycerophospholipid metabolism pathway influenced by gut microbiota
Applied and Environmental Microbiology 2025cited by 3position: middledoi
Supplementary Figure 9 from SPP1&lt;sup&gt;+&lt;/sup&gt; Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8&lt;sup&gt;+&lt;/sup&gt; T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma
2025cited by 0position: contributordoi
Supplementary Figure 8 from SPP1&lt;sup&gt;+&lt;/sup&gt; Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8&lt;sup&gt;+&lt;/sup&gt; T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma
2025cited by 0position: contributordoi
Supplementary Tables from SPP1&lt;sup&gt;+&lt;/sup&gt; Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8&lt;sup&gt;+&lt;/sup&gt; T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma
2025cited by 0position: contributordoi
Supplementary Figure 16 from SPP1&lt;sup&gt;+&lt;/sup&gt; Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8&lt;sup&gt;+&lt;/sup&gt; T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma
2025cited by 0position: contributordoi
Data from SPP1&lt;sup&gt;+&lt;/sup&gt; Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8&lt;sup&gt;+&lt;/sup&gt; T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma
2025cited by 0position: contributordoi
Supplementary Figure 12 from SPP1&lt;sup&gt;+&lt;/sup&gt; Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8&lt;sup&gt;+&lt;/sup&gt; T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma
2025cited by 0position: contributordoi
Supplementary Figure 2 from SPP1&lt;sup&gt;+&lt;/sup&gt; Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8&lt;sup&gt;+&lt;/sup&gt; T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma
2025cited by 0position: contributordoi
Supplementary Figure 13 from SPP1&lt;sup&gt;+&lt;/sup&gt; Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8&lt;sup&gt;+&lt;/sup&gt; T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma
2025cited by 0position: contributordoi
Supplementary Figure 15 from SPP1&lt;sup&gt;+&lt;/sup&gt; Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8&lt;sup&gt;+&lt;/sup&gt; T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma
2025cited by 0position: contributordoi
Supplementary Figure 1 from SPP1&lt;sup&gt;+&lt;/sup&gt; Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8&lt;sup&gt;+&lt;/sup&gt; T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma
2025cited by 0position: contributordoi
Supplementary Figure 7 from SPP1&lt;sup&gt;+&lt;/sup&gt; Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8&lt;sup&gt;+&lt;/sup&gt; T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma
2025cited by 0position: contributordoi
Supplementary Figure 19 from SPP1&lt;sup&gt;+&lt;/sup&gt; Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8&lt;sup&gt;+&lt;/sup&gt; T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma
2025cited by 0position: contributordoi
Supplementary Figure 17 from SPP1&lt;sup&gt;+&lt;/sup&gt; Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8&lt;sup&gt;+&lt;/sup&gt; T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma
2025cited by 0position: contributordoi
Supplementary Figure 6 from SPP1&lt;sup&gt;+&lt;/sup&gt; Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8&lt;sup&gt;+&lt;/sup&gt; T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma
2025cited by 0position: contributordoi
Supplementary Figure 3 from SPP1&lt;sup&gt;+&lt;/sup&gt; Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8&lt;sup&gt;+&lt;/sup&gt; T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma
2025cited by 0position: contributordoi
Supplementary Figure 18 from SPP1&lt;sup&gt;+&lt;/sup&gt; Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8&lt;sup&gt;+&lt;/sup&gt; T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma
2025cited by 0position: contributordoi
Supplementary Figure 4 from SPP1&lt;sup&gt;+&lt;/sup&gt; Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8&lt;sup&gt;+&lt;/sup&gt; T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma
2025cited by 0position: contributordoi
Supplementary Figure 14 from SPP1&lt;sup&gt;+&lt;/sup&gt; Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8&lt;sup&gt;+&lt;/sup&gt; T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma
2025cited by 0position: contributordoi
Supplementary Figure 10 from SPP1&lt;sup&gt;+&lt;/sup&gt; Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8&lt;sup&gt;+&lt;/sup&gt; T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma
2025cited by 0position: contributordoi
Supplementary Figure 5 from SPP1&lt;sup&gt;+&lt;/sup&gt; Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8&lt;sup&gt;+&lt;/sup&gt; T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma
2025cited by 0position: contributordoi
Supplementary Figure 11 from SPP1&lt;sup&gt;+&lt;/sup&gt; Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8&lt;sup&gt;+&lt;/sup&gt; T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma
2025cited by 0position: contributordoi
Effects of psychotherapy interventions on anxiety and depression in patients with gastrointestinal cancer: A systematic review and network meta-analysis
Journal of Psychosomatic Research 2024cited by 20position: middledoi
Prognostic value of computed tomography-derived fractional flow reserve in patients with diabetes mellitus and unstable angina
Cardiovascular Diabetology 2024cited by 6position: middledoi

Grants

HSI Implementation and Evaluation Project: Broadening STEM Participation Through Authentic Learning Experience
NSF2421426$799,9972024–2025PIRePORTER
Promoting Student Engagement and Success through Assistive Technology
NSF2225203$299,9792022–2024PIRePORTER
CEDAR: Short-Term Variability of the Upper Atmosphere during Stratospheric Sudden Warming Events
NSF1138784$331,6402012–2017PIRePORTER

Frequent collaborators

Jiejie Xu · Shanghai Medical College of Fudan University39 papers (2013–2026)Jianming Guo · Ministry of Education of the People's Republic of China37 papers (2014–2026) · 24 papers (2021–2026)Yang Qu · 23 papers (2025–2026) · 23 papers (2025–2026) · 23 papers (2025–2026) · 23 papers (2025–2026) · 23 papers (2025–2026) · 23 papers (2025–2026)Youqi Qiu · 23 papers (2025–2026)Jiyan Luo · 22 papers (2025–2025)Boyu Zhang · 22 papers (2025–2025)Yu Xia · China Meteorological Administration12 papers (2016–2021)Qi Bai · Sun Yat-sen University12 papers (2016–2021)Le Xu · Shandong University of Technology11 papers (2013–2021)Yu Zhu · Fudan University10 papers (2019–2021)Han Zeng · Fudan University9 papers (2020–2021)Ying Xiong · Aviation General Hospital8 papers (2016–2021)Yuan Chang · Fudan University7 papers (2020–2021)Yang Qu · Sichuan University7 papers (2016–2021)